### Daunorubicin

**Indication**: Myeloid leukaemia  
**ICD11 code**: 2C03.1

**INN**: Daunorubicin  
**Medicine type**: Chemical agent  
**List type**: Complementary

**Formulations**:
- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection
- 20 mg in vial (as hydrochloride) powder for injection
- 2 mg per mL in vial (as hydrochloride)
- 5 mg per mL in vial (as hydrochloride)

**EML status history**:
- First added in 1999 (TRS 895)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

**Sex**: All  
**Age**: Adolescents and adults

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**:
- Patents have expired in most jurisdictions  
- Read more about patents.

**Tags**: Cancer

**Wikipedia**: Daunorubicin

**DrugBank**: Daunorubicin

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.